Ann: GBM Agile Update, page-119

Hey H don't you wish you'd stayed out?

We don't know the data but Agile does and they made a decision. Logically it follows that the data is not ideal or that one of the other drugs is outperforming it. This whole BS about a few drugs going through in tandem did not eventuate. Its not winner takes all he said. JG was wrong I knew it. I sadi it at the time.

Can they pivot to DPIG which is having good results maybe but GBM is a dead.

They shouldn't stuff around cause uncertainty is worse than bad results. They have to share the vision even a weak one. No vision equals no leadership thats what he is paid to do.

Matt (get it) Dunn wouldn't just sit quitely he'd pivot and move forward. JG is the weak point. The drug is the product the company is paper. JG is the company and must take the reigns or quit. Let the Friend run it in the interim. Sack the non event CFO.